Multiple Sclerosis Research Repository

-“…the evidence in RMS drug labels for a reduction in disability progression shows smaller effect sizes and lacks confirmation in a second trial for some drugs” (Cross Discipline Team Leader Review, Product Quality, page 4)

-Rebif showed a reduction in patients with disability progression sustained for 3 months in 8 to 11 percent of patients (page 4)